They would have had to payback the $500k otherwise, so it is material.
The language seems promising too - "Once the results are reported, Bod intends to submit the dossier to the TGA for their review of what is anticipated to be the first Schedule 3 CBD product to be made available in Australia."
- Forums
- ASX - By Stock
- Ann: Updates on Phase IIB clinical trial of Schedule 3 CBD
They would have had to payback the $500k otherwise, so it is...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online